Opaleye Management Inc. Uro Gen Pharma Ltd. Transaction History

Opaleye Management Inc.

$548 Million
Q3 2024

A detailed history of Opaleye Management Inc. transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Opaleye Management Inc. holds 404,100 shares of URGN stock, worth $4.67 Million. This represents 0.94% of its overall portfolio holdings.

Number of Shares

404,100

Previous 412,000 1.92%

Holding current value

$4.67 Million

Previous $6.91 Million 25.76%

% of portfolio

0.94%

Previous 1.77%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$12.7 - $17.92 $100,330 - $141,568	-7,900 Reduced 1.92%	404,100 $5.13 Million
Q2 2024 Aug 14, 2024	BUY	$12.72 - $19.2 $1.81 Million - $2.73 Million	142,000 Added 52.59%	412,000 $6.91 Million
Q1 2024 May 15, 2024	SELL	$13.81 - $19.33 $690,500 - $966,499	-50,000 Reduced 15.63%	270,000 $4.05 Million
Q3 2023 Nov 14, 2023	SELL	$8.84 - $22.64 $2.21 Million - $5.66 Million	-250,000 Reduced 43.86%	320,000 $4.48 Million
Q2 2023 Aug 14, 2023	BUY	$8.75 - $14.29 $568,750 - $928,850	65,000 Added 12.87%	570,000 $5.9 Million
Q1 2023 May 12, 2023	BUY	$7.99 - $11.02 $130,588 - $180,110	16,344 Added 3.34%	505,000 $4.67 Million
Q4 2022 Feb 10, 2023	BUY	$7.55 - $11.96 $688,227 - $1.09 Million	91,156 Added 22.93%	488,656 $4.33 Million
Q3 2022 Nov 14, 2022	BUY	$7.21 - $9.41 $1.15 Million - $1.49 Million	158,830 Added 66.55%	397,500 $3.31 Million
Q2 2022 Aug 15, 2022	BUY	$5.12 - $8.74 $1.22 Million - $2.09 Million	238,670 New	238,670 $1.96 Million

Others Institutions Holding URGN

# of Institutions

130

Shares Held

35.9M

Call Options Held

22K

Put Options Held

93.8K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $263M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Opaleye Management Inc. with notifications on news.

Account

Opaleye Management Inc. Uro Gen Pharma Ltd. Transaction History